Mast Cell Tumors: The Latest and Greatest
1.0 CE Credit Hour / Philip Bergman, DVM, MS, PhD, DACVIM
Philip Bergman, DVM, MS, PhD, DACVIM
Dr. Bergman is the Director of Clinical Studies for Mars Veterinary Health. He is the principal veterinary investigator for the fully licensed canine melanoma vaccine (Oncept). Dr. Bergman is an adjunct faculty member of the Memorial Sloan-Kettering Cancer Center. Prior to Dr. Bergman joining VCA, he served as the Chief Medical Officer for BrightHeart Veterinary Centers from July 2007 to August 2011; from 1999 to June 2007 he was the head of the Donaldson-Atwood Cancer Center at AMC. After finishing veterinary school from Colorado State in 1990, he was an intern at Kansas State (90-91) and returned to CSU for his medical oncology residency (91-94) and then completed a PhD Fellowship in human cancer biology from the M.D. Anderson Cancer Center in Houston (94-99). He was previously Chair of the ACVIM Board of Regents and President of the Veterinary Cancer Society. Dr. Bergman has been an veterinary oncologist at Katonah Bedford Veterinary Center since 2007.
Overview:
Mast cell tumors are extremely common tumors in the dog and are now beginning to be understood as a disease entity in the cat. The diagnostic, prognostic and therapeutic approach to mast cell tumors in dogs and cats will be presented. In addition, the latest in therapeutic and prognostic alternatives will be presented.
Learning Objectives:
- Better understand the differences between the historical Patnaik 3 grade system vs the newer Michigan State low vs high 2 grade system
- Become more fluent in the risk factors associated with canine mast cell tumors
- Better understand the current recommendations for the level of pre-operative staging for dogs with MCT
- Recognize the main indications for Palladia use in dogs with MCT
This course is RACE-approved for 1.0 continuing education credits hours in jurisdictions that accept RACE-approval.
